
Imugene Ltd (ASX: IMU) shares are catching the eye on Thursday morning.
In early trade, the ASX 300 healthcare stock is up almost 5% to 11 cents.
Why is this ASX 300 healthcare stock storming higher?
Investors have been buying the clinical stage immune-oncology company’s shares after responding positively to an announcement.
According to the release, the company has received a notice of grant from the Chinese Patent Office. This follows earlier grants in Japan and South Korea.
The granted claims protect the ASX 300 stock’s oncolytic virotherapy, CF33, including VAXINIA (CF33-hNIS) and CHECKvacc (CF33-hNIS-antiPDL1).
This is a big boost for the company given that China is the largest pharmaceutical market in Asia.
What is CF33?
CF33 is a chimeric vaccinia poxvirus from the lab of inventor Professor Yuman Fong, Chair of Sangiacomo Family Chair in Surgical Oncology at City of Hope, and a noted expert in the oncolytic virus field.
Oncolytic viruses are designed to both selectively kill tumour cells and activate the immune system against cancer cells. Imugene notes that they have the potential to improve clinical response and survival.
The release explains that the patent is titled “Chimeric poxvirus composition and uses thereof” and protects the method of composition and method of use of Imugene’s licensed oncolytic virotherapy all the way out to 2037.
‘Important patent milestone’
The ASX 300 stock’s managing director and CEO, Leslie Chong, was pleased with the news. She said:
Imugene receiving these patent grants for the CF33 family of oncolytic viruses is a crucial step forward and with China, Japan, and South Korea being the largest healthcare markets in Asia, this is a particularly important patent milestone.
What is Imugene?
Imugene is a clinical stage immuno-oncology company with a focus on developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
It claims to have unique platform technologies that seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
As well as CF33, the ASX 300 stock’s pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers.
Unfortunately, over the last 12 months, the company’s shares have underperformed the market. For example, despite today’s gain, the Imugene share price remains down 15% since this time last year.
The post Guess which ASX 300 healthcare stock is storming higher on Chinese patent news appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…
See The 5 Stocks
*Returns as of 1 February 2024
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Should I rush to buy this ASX 200 giant currently near its 52-week low?
- If you start investing today, when could you retire?
- Should I buy BHP or Rio Tinto shares in April?
- 3 top ASX REITs to buy in April 2024
- The tiny ASX stock that could surge on this pending government decision
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/8XyMLoG








